🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07067476
Starting soon Not applicable

Instant Flush Redness Clinical Efficacy Study

NCT07067476 · tracked via the Priya Life Science China tracker
Sponsor
ChinaNorm
Phase
Not applicable
Started
2025-07-15
Last updated
2025-07-16

Condition(s) studied

Sensitive Skin

Investigational drug(s) / intervention(s)

Instant Anti-Redness Emulsion (FLA#2039188 43)Purified Water (Control)

Instant Anti-Redness Emulsion (FLA#2039188 43): A topical emulsion not yet marketed, developed to relieve skin redness. It contains panthenol and is applied once to the test side of the face after heat-induced redness.

Purified Water (Control): 0.3g of water is applied to the control side of the face. Used as placebo comparator to evaluate the redness-relieving efficacy of the test emulsion.

Study summary

The goal of this clinical trial is to learn if an anti-redness emulsion can help lower facial redness caused by heat in healthy adult women. The main questions it aims to answer are:

* Does the anti-redness emulsion lower facial redness better than purified water?
* Is the product safe and comfortable to use?

Researchers will compare the anti-redness emulsion to purified water using a split-face method.

Participants will:

* Receive infrared light on their face to trigger redness
* Apply the anti-redness emulsion to one side of their face and purified water to the other side
* Have their facial redness measured at different time points using photography, imaging devices, and skin redness tests
* Answer questions about their experience with the products

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Chinese women aged from 20-40 years old. 2. Self-declared mild sensitive skin. 3. Self-declare with skin concerns of redness and easy to flush. 4. Willing to be exposed to infrared light on the facial skin to induce facial redness(can tolerate heat sensation on the face). 5. Clinical grading of skin redness (visual) ≥ 4 after infrared light induction (7-8 mins) by dermatologist. 6. No disagreement of dermatologist because of other reasons that exclude the parficipation of the subject. 7. In general good health at the time of the study. 8. Willing and able to participate as evidenced by signing of informed consent and photo release Exclusion Criteria: 1. Allergic to infrared light 2. Pregnant or breast-feeding woman or woman planning pregnancy during the study. 3. Subject deprived of rights by a court or administrative order. 4. Major subject to a guardianship order. 5. Subject residing in a health or social care establishment. 6. Patient in an emergency setting 7. Subject with a skin disease in the test areas (particularly e.g, acne, rosacea, eczema). 8. Subjects with history, of atopy, allergic reactions, irritation or intense discomfort feelings to topical-use products, medication, cosmetic: or personal care products or ingredients. 9. Subject presenting a stable or progressive serious disease (per investigator's assessment). 10. Immuno-compromised subject. 11. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment). 12. Subjects regularly practicing aquatic or nautical sports. 13. Subjects regularly attending a sauna. 14. Subject with cardiovascular or circulatory history. 15. Subject with a history of skin cancer or malignant melanoma. 16. Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune-suppressants in the last 6 months before study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072 Shanghai China

More ChinaNorm trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07067476 on ClinicalTrials.gov ↗ ← All trials in China